Gain Therapeutics

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Luca Benatti to Chair SAB Dr. Luca Benatti to Chair SAB

Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)

BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the appointment of Matthias Alder as Chief Operating Officer to advance the Company's strategic and operational objectives, including the establishment of additional industry partnerships and the transition of the Company's lead program in Gaucher and Parkinson's Disease into clinical trials, which is expected to occur in 2022.

Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

Image by National Cancer Institute on Unsplash Medical and technological advancements are extending our lifespan. Unfortunately, as human life expectancy rises, so does the risk of people developing a degenerative disease such as Alzheimer's, Parkinson's, or diabetes.

Gain Therapeutics' SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding

Conference Dates: September 27th-30th Conference Dates: September 27th-30th

Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

- Conference Dates: September 20 th -23 rd -

Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company's proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.

Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

Gain Therapeutics Inc (NASDAQ: GANX) are trading higher Wednesday after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher and Parkinson's disease. Gain Therapeutics identified the two lead STAR candidates through its proprietary SEE-Tx platform.

Why Gain Therapeutics Shares Are Trading Higher Today

The topline data from a study conducted at the University of Maryland School of Medicine (UMSOM) by Gain Therapeutics Inc (NASDAQ: GANX) evaluating two lead Structurally Targeted Allosteric Regulators (STARs) compounds, GT-02287 and GT-02329, for Gaucher and GBA1 Parkinson's Disease, demonstrated positive effects on all tested phenotypes. The study used human induced pluripotent stem cells (iPSC) derived from GD and GBA-associated Parkinson's disease patients.

Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study

The stock price of Gain Therapeutics Inc (NASDAQ: GANX) increased by over 25% pre-market. This is why it happened.

GANX Stock: Over 25% Increase Pre-Market Explanation

GT-02287and GT-02329 compounds display positive effects on GCase activity  and related parameters ---  Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and α-synuclein-p129 levels  ---  Comprehensive study results to be presented at Michael J. Fox Foundation's upcoming Innovating from Drug Discovery to the Clinic: Novel Approaches to PD Therapeutic Development webinar  ---  IND-initiating study planned for Q4'21

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson's Disease

BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13th - 15th.

Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathies including Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease --- $43.2 Million in Cash as of June 30, 2021, Provides Runway into Second half of 2023 and a Strong  Cash Position to Advance the Company's Programs

Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 – 10.

Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases

Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders

BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the Jefferies Virtual Healthcare Conference being held on June 1 – 4.

Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference

BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the 2021 RBC Capital Markets Global Healthcare Virtual Conference and at the Oppenheimer Rare & Orphan Disease Summit, both taking place in May.

Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May

Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collaboration agreement with Zentalis Pharmaceuticals (Nasdaq: ZNTL) to discover new product candidates for the treatment of cancer --- Presented positive pre-clinical lysosomal storage target data at annual WorldSymposium™ --- Expect to complete proof of concept animal studies and begin IND-enabling trials in the second half of 2021

Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results

Compounds reverse the neurodegenerative process observed in a Parkinson's disease in vivo model

Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson's Disease & Related α-synucleopathies at the XXVI IAPRD World Congress

BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the B. Riley Securities' Virtual Neuroscience Conference being held on April 28 - 29.

Gain Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience Conference

Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference

Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress

Collaboration to use Gain's proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously  difficult-to-drug oncology targets

Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals

BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of the underwriters' overallotment option to purchase 545,454 additional shares of common stock, at a public offering price of $11.00 per share. The gross proceeds to Gain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gain, were approximately $46 million.

Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option to Purchase Additional Shares

AFC Gamma

Connect Biopharma Holdings

Finch Therapeutics Group

Jowell Global

Duckhorn Portfolio

Sun Country Airlines

Instil Bio

Tuya

Vine Energy

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raised $915 million at an $11.8 billion market cap.

News for Gain Therapeutics Stock (GANX)